Table 2.
Regular use of analgesics and ovarian cancer risk in the Nurses Health Studies (NHS/NHS-II) and in the New England Ovarian Cancer Case-Control Study (NECC)*
| Nurses Health Studies (NHS/NHS-II) | NECC | Pooled | |||||
|---|---|---|---|---|---|---|---|
| cases N(%) | controls N(%) | OR (95% CI)† | cases N(%) | controls N(%) | OR (95% CI)† | OR (95% CI)†‡ | |
| N§ | 233 | 663 | 1120 | 1160 | |||
| Regular use of Aspirin ‡ | |||||||
| No | 148(68) | 426(68) | 1.00 | 1000(89) | 1013(87) | 1.00 | 1.00 |
| Yes | 69(32) | 202(32) | 0.91(0.64, 1.31) | 120(11) | 147(13) | 0.80(0.62, 1.05) | 0.84(0.68, 1.04) |
| Regular use of non-aspirin NSAIDs ‖¶ | |||||||
| No | 153(85) | 422 (85) | 1.00 | 1018(91) | 1020(88) | 1.00 | 1.00 |
| Yes | 26(15) | 72 (15) | 0.95 (0.58, 1.56) | 102(9) | 140(12) | 0.75 (0.57, 0.99) | 0.79 (0.62, 1.01) |
| Regular use any NSAIDs ‖¶ | |||||||
| No | 137(61) | 410(63) | 1.00 | 914(82) | 907(78) | 1.00 | 1.00 |
| Yes | 88(39) | 244(37) | 0.99(0.70, 1.39) | 206(18) | 253(22) | 0.80(0.65, 0.99) | 0.85(0.71, 1.02) |
| Regular use of Acetaminophen ‖ | |||||||
| No | 180 (95) | 486 (91) | 1.00 | 1041(93) | 1063(92) | 1.00 | 1.00 |
| Yes | 10 (5) | 49 (9) | 0.55 (0.26, 1.13) | 79(7) | 97(8) | 0.90 (0.65, 1.23) | 0.78 (0.51, 1.21) |
Restricted to Caucasian participants with genotyping data
NHS/NHS-II: Conditional logistic regression stratified on matching factors (i.e. age, menopause status at blood collection and diagnosis, PMH use at blood collection, date, time and fasting status at blood collection, DNAtype); NECC: Unconditional logistic regression adjusted forage (cont), study center (MA/NH). NHS/NHS-II and NECC: All models additionally adjusted for parity, duration of OC use (months), history of tubal ligation (y/n), PMH use (never/past/current), and menopausal status (pre/post)
Estimates pooled using DerSimonian and Laird random effects models: all P-het >0.22
Numbers may not add up to total N due to missing information on analgesic use.
In NHS/NHS-II, ≥2 days/week in the 2-4 years preceding ovarian cancer diagnosis. In NECC, ≥2 tablets/week for 6 months in the year preceding
In the NECC, “non-aspirin NSAIDs” refers primarily to ibuprofen